FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
FDA澄清了關於複合藥物的政策，因爲國家GLP-1供應開始穩定；不打算對因依賴於替戈氨酸注射的情況而違反FD&C法案的複合藥物採取行動。
FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection
FDA澄清了針對複合藥物製劑的政策，因爲全國GLP-1的供應開始穩定；不打算對複合藥物製劑採取行動，以應對因依賴Tirzepatide注射而違反FD&C法的情況。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間